

参考文献

1. Khan M H, Khalil A, Rashid H. Evaluation of the p53 Arg72Pro polymorphism and its association with cancer risk: a HuGE review and meta-analysis.[J]. Genetics Research, 2015, 97(97):e7.
2. Soussi T, Bérout C. Assessing TP53 status in human tumours to evaluate clinical outcome [J]. Nature Reviews Cancer, 2001, 1(3):233-40.
3. Ahmed A A, Etemadmoghadam D, Temple J, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary [J]. Journal of Pathology, 2010, 221(1):49-56.
4. Hussain S P, Schwank J, Staib F, et al. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer[J]. Oncogene, 2007, 26(15):2166.
5. Stacey S N, Sulem P, Jonasdottir A, et al. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility [J]. Nature Genetics, 2011, 43(11):1098.
6. Kurose K, Gilley K S, Watson P H, et al. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas [J]. Nature Genetics, 2002, 32(3):355.
7. Rausch T, Jones D W, Zapatka M, et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations [J]. Cell, 2012, 148(1-2):59.
8. Okada Y, Hurwitz E E, Esposito J M, et al. Selection pressures of TP53 mutation and microenvironmental location influence epidermal growth factor receptor gene amplification in human glioblastomas [J]. Cancer Research, 2003, 63(2):413-6.
9. Arnault J P, Mateus C, Escudier B, et al. Skin tumors induced by sorafenib; paradoxical RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1[J]. Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2012, 18(1):263.
10. Walsh T, Casadei S, Coats K H, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.[J]. Jama, 2006, 295(12):1379.
11. Olivier M, Langerød A, Carrieri P, et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.[J]. Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2006, 12(4):1157.
12. Nagai M A, Miracca E C, Yamamoto L, et al. TP53 genetic alterations in head-and-neck carcinomas from Brazil[J]. International Journal of Cancer, 2015, 76(1):13-18.
13. Liu Y, Zhang X, Han C, et al. TP53 loss creates therapeutic vulnerability in colorectal cancer[J]. Nature, 2015, 520(7549):697.
14. Wong T N, Ramsingh G, Young A L, et al. The Role of TP53 Mutations in the Origin and Evolution of Therapy-Related AML [J]. Nature, 2015, 518(7540):552.
15. Takami H, Yoshida A, Fukushima S, et al. Revisiting TP53 Mutations and Immunohistochemistry--A Comparative Study in 157 Diffuse Gliomas [J]. Brain Pathology, 2015, 25(3):256.
16. Sammons M A, Zhu J, Drake A M, et al. TP53 engagement with the genome occurs in distinct local chromatin environments via pioneer factor activity. [J]. Genome Research, 2015, 25(2):179-188.
17. Masica D L, Li S, Douville C, et al. Predicting survival in head and neck squamous cell carcinoma from TP53, mutation[J]. Human Genetics, 2015, 134(5):497-507.
18. Suzuki K, Mori I, Nakayama Y, et al. Radiation-induced senescence-like growth arrest requires TP53 function but not telomere shortening.[J].